ArticleACS infectious diseases2018
New Class of Adjuvants Enables Lower Dosing of Colistin Against Acinetobacter baumannii.
Article in ACS infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Colistin Resistance in Bacteria: Current Updates on Mechanism of Action and Combating Strategies.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Catechol-substituted siderophore colistin exhibits superior antimicrobial activity than its unmodified polypeptide counterpart.BMC chemistry · 2025Article
- Colistin Resistance Mechanism and Management Strategies of Colistin-ResistantPathogens (Basel, Switzerland) · 2024Review
- Sensitization of Gram-Negative Bacteria to Aminoglycosides with 2-Aminoimidazole Adjuvants.Antibiotics (Basel, Switzerland) · 2023Article
- Inhibiting fatty acid synthesis overcomes colistin resistance.Nature microbiology · 2023Article
- The VirtuousAntibiotics (Basel, Switzerland) · 2023Review
- Polymyxins induce lipid scrambling and disrupt the homeostasis of Gram-negative bacteria membrane.Biophysical journal · 2022Article
- Inhibitors ofPharmaceuticals (Basel, Switzerland) · 2022Article
- Benzydamine Reverses TMexCD-TOprJ-Mediated High-Level Tigecycline Resistance in Gram-Negative Bacteria.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Review
- Screening an Established Natural Product Library Identifies Secondary Metabolites That Potentiate Conventional Antibiotics.ACS infectious diseases · 2020Article
- Augmenting the Activity of Macrolide Adjuvants againstACS medicinal chemistry letters · 2020Article
- A novel colistin adjuvant identified by virtual screening for ArnT inhibitors.The Journal of antimicrobial chemotherapy · 2020Article
- Venturicidin A, A Membrane-active Natural Product Inhibitor of ATP synthase Potentiates Aminoglycoside Antibiotics.Scientific reports · 2020Article
- A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.Antimicrobial agents and chemotherapy · 2020Article
- Polymyxin B Loosens Lipopolysaccharide Bilayer but Stiffens Phospholipid Bilayer.Biophysical journal · 2020Article
- Small Molecule Adjuvants Potentiate Colistin Activity and Attenuate Resistance Development inInfection and drug resistance · 2020Article
- Galleria mellonella as a consolidated in vivo model hosts: New developments in antibacterial strategies and novel drug testing.Virulence · 2019Review
- Second-Generation Tryptamine Derivatives Potently Sensitize Colistin Resistant Bacteria to Colistin.ACS medicinal chemistry letters · 2019Article
- Using Small-Molecule Adjuvants to Repurpose Azithromycin for Use against Pseudomonas aeruginosa.ACS infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Antibiotic resistance has become increasingly prevalent over the past few decades, and this combined with a dearth in the development of new classes of antibiotics to treat multidrug resistant Gram-negative infections has led to a significant global health problem and the increased usage of colistin as the last resort antibiotic. Colistin, however, presents dose dependent toxicity in the clinic. One potential approach to combatting this problem is the use of an antibiotic adjuvant, a compound that is nontoxic to the bacteria that enhances the potency of colistin and ultimately allows for reducing dosing. Herein, we present a new urea-containing class of 2-aminoimidazole-based adjuvants that potentiates colistin activity against colistin-sensitive Acinetobacter baumannii. Lead compounds enabled 1000-fold reduction in the minimum inhibitory concentration of colistin in vitro and showed efficacy in a Galleria mellonella infection model, representing the first step toward validating the potential of employing these adjuvants to lower colistin dosage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.